Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bristol-Myers Squibb
Bristol-Myers Squibb
Study Director - Kristen Hege
Celgene
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Universitaire Ziekenhuizen Leuven
Leuven, Flemish Brabant, Belgium
- Local Institution - 201
Leuven, Belgium
- Local Institution - 301
Toronto, Ontario, Canada
- Princess Margaret Cancer Centre
Toronto, Canada
- Centre Hospitalier Regional Universitaire de Lille-Hopital Calude Huriez Service Des Maladies Du Sang
Lille, Hauts-de-France, France
- Centre Hospitalier Universitaire de Nantes - Hotel Dieu
Nantes, Pays de la Loire Region, France
- Local Institution - 402
Lille, France
- Local Institution - 401
Nantes, France
- Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato
Heidelberg, Baden-Wurttemberg, Germany
- University of Tübingen
Tübingen, Baden-Wurttemberg, Germany
- Universitatsklinikum Würzburg
Würzburg, Bavaria, Germany
- Local Institution - 502
Heidelberg, Germany
- Local Institution - 503
Tübingen, Germany
- Local Institution - 501
Würzburg, Germany
- Azienda Ospedaliero Universitaria Di Bologna Policlinico
Bologna, Emilia-Romagna, Italy
- Local Institution - 602
Bergamo, Italy
- Ospedali Riuniti Di Bergamo
Bergamo, Italy
- Local Institution - 601
Bologna, Italy
- Tokai University Hospital
Isehara, Kanagawa, Japan
- Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
- Japan Red Cross Medical Center
Shibuya-ku, Tokyo, Japan
- Local Institution - 803
Isehara City, Kanagawa, Japan
- Local Institution - 801
Shibuya-ku, Japan
- Local Institution - 802
Shimotsuke, Japan
- Local Institution - 804
Shinjuku, Japan
- Tokyo Women'S Medical University Hospital
Shinjuku, Japan
- Hospital Universitari Germans Trias I Pujol Can Ruti
Badalona, Barcelona, Spain
- Clinica Universidad de Navarra
Pamplona, Navarre, Spain
- Local Institution - 702
Badalona (Barcelona), Spain
- Local Institution - 701
Pamplona, Spain
- Local Institution - 108
San Francisco, California, United States
- University of California - San Francisco
San Francisco, California, United States
- Emory University
Atlanta, Georgia, United States
- Local Institution - 103
Atlanta, Georgia, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Local Institution - 106
Boston, Massachusetts, United States
- Local Institution - 107
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Local Institution - 105
Rochester, Minnesota, United States
- Mayo Clinic
Rochester, Minnesota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Dec 2017
- Primary completion
- 20 Dec 2023
- Completion
- 20 Dec 2023
- Last update posted
- 23 May 2025
- Registered enrollment
- 149
- Registry id
- NCT03361748
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.